Orexigen trị liệu inc stock phnadjr

Orexigen trị liệu inc stock

12.03.2021

Younkin84942

Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

Orexigen Therapeutics, Inc. Overview: Detailed price quote, earnings report, user sentiment and news. The stock analysis for Orexigen Therapeutics, Inc. (OREX) is based on the analysis and stock picks of our best trading systems. By aggregating the opinions and predictions of our best trading systems (trading bots), we come up with a general prediction.

Orexigen Therapeutics, Inc. Overview: Detailed price quote, earnings report, user sentiment and news.

REX | Complete Orex Minerals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially all of the assets of the company, subject to court approval.

REX | Complete Orex Minerals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

SAN DIEGO, Oct. 24, 2012 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it intends to offer shares of its common stock in an underwritten public offering.In Orexigen Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of pharmaceutical product candidates for the treatment of obesity. Its product candidate, NB32, is an investigational medicine for weight loss and the maintenance of weight loss; and Empatic used for the adjunctive treatment of partial seizures, a form of epilepsy. Orexigen Therapeutics, Inc. 's OREX shares were up 4.2% after the company announced that it has entered into a commercialization and distributorship agreement with Valeant Canada, a subsidiary of Orexigen Therapeutics, Inc. (NASDAQ:OREX) Curiously, Orexigen Therapeutics, Inc. (NASDAQ:OREX) traded lower after a United States District Court issued a favorable ruling in a patent litigation case involving three patents for its obesity drug Contrave. Shares of the company fell 3.43% in Friday’s trading session to end the week at $1.97 a share.

Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

Discover historical prices for OREX stock on Yahoo Finance. View daily, weekly or monthly format back to when Orexigen Therapeutics, Inc. stock was issued. OREX / Orexigen Therapeutics, Inc. / Baupost Group LLC/MA - NONE Activist Investment. 2019-06-04 sec.gov - 10 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 05 )* Orexigen Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 686164302 (CUSIP … Blame This for Orexigen Therapeutics, Inc.'s Mind-Numbingly Bad 2015 It was expected to be Orexigen's greatest selling point, but this miscue turned into a nightmare for the company's weight Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity. La Jolla , California , United States Industries Biotechnology , Health Care , Pharmaceutical Headquarters Regions Greater San Diego Area , West Coast , Western US Founded Date 2002 Founders Eckard Weber Operating Status Active Funding Status IPO Last Funding Type Post-IPO Equity Number of Employees 101 SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity. The company is based in La Jolla, California and was established by Eckard Weber in 2002. As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX. The company has a single product, Contrave, approved for use in the United States in …